Magnetic Labeling and Tracking of Cells Using Magnetodendrimers As MR Contrast Agent

Josephus Wilhelmus Maria Bulte,Trevor Douglas,Brian P. Witwer,S. C. Zhang,Bobbi K. Lewis,Peter van Gelderen,Ian D. Duncan,J A Frank

2002-01-01

Abstract:INTRODUCTION: During the last few years, the therapeutic use of stem and progenitor cells as a substitute for malfunctioning endogenous cells has received much attention. Unlike their use in animal models, the introduction of therapeutic cells in patients will require techniques that can monitor their tissue biodistribution non-invasively. Among the different imaging modalities, magnetic resonance (MR) imaging offers both near-cellular (i.e. 50 μm) resolution and whole-body imaging capability. In order to be visualized, cells must be labeled with an intracellular marker that can be detected by MR imaging. Superparamagnetic iron oxide nanoparticles provide currently the highest sensitivity when used as MR contrast agent. Following their covalent linking to anti-transferrin receptor internalizing monoclonal antibodies [1] or small HIV-tat peptides [2], they can be used as cellular contrast agent allowing MR tracking of magnetically labeled progenitor cells following transplantation. We have recently developed a new type of iron oxide nanoparticle, magnetodendrimers, that has excellent magnetic and NMR relaxation enhancing properties [3] and, due to its coating with a dendrimer as transfection agent, is effciently taken up by a variety of mammalian cells [4].